GLUCAGON-LIKE PEPTIDE 1: BIOChEMISTRy, SECRETION AND MAIN PhySIOLOGICAL EFFECTS
نویسندگان
چکیده
the peptide hormone glucagon-like peptide 1 (glp-1), produced in the intestinal l-cells by differential processing of proglucagon, is secreted in response to meal intake. glp-1 affects various systems, the gastrointestinal and pancreatic systems being the best studied, either by direct binding to the glp-1 receptor, at the target-cells surface, or indirectly as a result of paracrine regulation. because of glp-1’s roles, in augmenting glucose-induced insulin secretion and modulating food intake, currently glp-1 receptor agonists are being studied for diabetes and obesity therapy. KEywORDS peptide hormone; glucagon-like peptide 1, glp-1, incretin, Diabetes mellitus type 2, obesity COMO REFERENCIAR ESTE ARTIGO: silVA, Amélia m. [et al.] glucagon-like peptide 1: biochemistry, secretion and main physiological effects. Revista da Faculdade de Ciências da Saúde. porto : edições universidade Fernando pessoa. issn 1646-0480. 6 (2009) 104-113. 106
منابع مشابه
The physiology of glucagon-like peptide 1.
Glucagon-like peptide 1 (GLP-1) is a 30-amino acid peptide hormone produced in the intestinal epithelial endocrine L-cells by differential processing of proglucagon, the gene which is expressed in these cells. The current knowledge regarding regulation of proglucagon gene expression in the gut and in the brain and mechanisms responsible for the posttranslational processing are reviewed. GLP-1 i...
متن کاملGlp - 1
Glucagon like peptide-1 (GLP-1) is a GI hormone produced in endocrine cells in the distal small intestine by alternative processing of the proglucagon gene product. In humans it is a 29 amino acid peptide with an amidated carboxyl terminal. It is one of the established incretin hormones as its main action is to promote insulin secretion in response to oral glucose. It has a short half-life in b...
متن کاملTolerance Does Not Develop Toward Liraglutide's Glucose-Lowering Effect.
Context Glucagon-like peptide-1 receptor agonists are popular antidiabetic drugs with potent glucose-lowering effects and low risk of hypoglycemia. Animal experiments and human data indicate that tolerance develops toward at least some of their effects (e.g., gastric motility). Whether tolerance develops toward the glucose-lowering effect of glucagon-like peptide-1 receptor agonists has never b...
متن کاملClinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus
The glucagon-like peptide (GLP)-1 receptor agonist lixisenatide (Lyxumia(®)) was approved for marketing by the European Medicines Agency in February 2013 and has been evaluated in a clinical study program called GetGoal. Lixisenatide activates the GLP-1 receptor and thereby exercises the range of physiological effects generated by GLP-1, which consist of increased insulin secretion, inhibition ...
متن کاملG-protein-coupled receptors and islet function-implications for treatment of type 2 diabetes.
Islet function is regulated by a number of different signals. A main signal is generated by glucose, which stimulates insulin secretion and inhibits glucagon secretion. The glucose effects are modulated by many factors, including hormones, neurotransmitters and nutrients. Several of these factors signal through guanine nucleotide-binding protein (G protein)-coupled receptors (GPCR). Examples of...
متن کامل